Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02126696
Other study ID # CART-1
Secondary ID
Status Completed
Phase N/A
First received April 28, 2014
Last updated April 19, 2016
Start date May 2014
Est. completion date December 2015

Study information

Verified date April 2016
Source Swiss Tropical & Public Health Institute
Contact n/a
Is FDA regulated No
Health authority Lesotho: Ministry of Health
Study type Observational

Clinical Trial Summary

This study is conducted in a cohort of HIV-positive patients on first-line anti-retroviral therapy (ART) in rural health facilities in Lesotho, Southern Africa. It examines virologic treatment failure as well as chronic communicable and non-communicable comorbidities among patients on ART. The study has two phases. Phase 1 consists of a cross-sectional survey to determine prevalence of treatment failure as well as the prevalence of the following comorbidities: diabetes mellitus, arterial hypertension, dyslipidemia, depression, alcohol use disorder, hepatitis B and hepatitis C. Phase 2 is a cohort study, where patients with treatment failure or a comorbidity or both are followed-up for 12 months.


Description:

Background

Owing to successful scale-up and decentralization of anti-retroviral therapy (ART) in rural Lesotho, the number of persons infected with HIV who stay alive increased dramatically. The new situation of HIV having turned from a deadly disease into a chronic but manageable condition creates a new challenge to health care providers in rural facilities of the country. Patients on long-time ART may suffer from comorbidities endangering the success of ART and their health and/or from ART-failure due to development of resistance of the virus. The magnitude of the burden of comorbidities as well as ART- failure has not been examined extensively in Lesotho yet.

Objectives of the Study

The study has six major objectives:

1. To assess the prevalence of virologic failure and genotype-resistance of HIV among patients on ART in rural Lesotho.

2. To assess the prevalence of hepatitis C and hepatitis B among patients on ART in rural facilities in Lesotho

3. To assess the prevalence of diabetes mellitus, arterial hypertension and dyslipidaemia among patients on ART in rural facilities in Lesotho

4. To assess the prevalence of depression and alcohol use disorder among patients on ART in rural facilities in Lesotho

5. To examine associations between chronic comorbidities and virologic outcome among patients on ART in rural Lesotho

6. To follow-up patients with virologic failure and/or comorbidity(ies) among patients on ART in rural Lesotho

Design/Methods

The study is planned to take place in two districts of Lesotho: Botha-Bothe and Thaba-Tseka. Prevalence of the selected comorbidities is measured in a cross-sectional, facility-based survey in eight health centers and two hospitals from the two districts. Patients with a detectable viral load will receive enhanced adherence counselling and a second viral load measurement after 2-3 months. In case of confirmed virologic failure, a genotype resistance testing will be done before patients are switched to second-line. Patients with specific comorbidities or patients with virologic failure who had been switched to second-line ART will be followed-up in a cohort study 12-18 months after the survey.

Expected Results and Impact

Prevalence of the selected comorbidities will inform the Ministry of Health as well as its implementing partners on which chronic conditions might be most urgent to be addressed among patients on ART in Lesotho and the national HIV-programme may be used to leverage on for other chronic conditions. Data on virologic failure will inform on the prevalence of virologic failure among a previously not virologically monitored cohort. Moreover it will provide data on the resistance patterns among patients who fail on first-line ART and on the one-year outcome after switch to a second-line regimen.


Recruitment information / eligibility

Status Completed
Enrollment 1754
Est. completion date December 2015
Est. primary completion date November 2014
Accepts healthy volunteers No
Gender Both
Age group 6 Months and older
Eligibility Inclusion Criteria:

- on anti-retroviral therapy = 6 months

- informed consent given

Exclusion Criteria:

- on anti-retroviral therapy for < 6 months or documented treatment interruption of = 7 days during the last 3 months

- children < 16 years without the caretaker who can provide informed consent for study participation

- patients on second-line anti-retroviral therapy

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Locations

Country Name City State
Lesotho Seboche Hospital Butha-Buthe
Lesotho Paray Hospital Thaba-Tseka

Sponsors (5)

Lead Sponsor Collaborator
Swiss Tropical & Public Health Institute Central Laboratories, University Hospitals Basel-Land (Liestal), SolidarMed - Swiss Organization for Health in Africa, Swiss Foundation for Excellence and Talent in Biomedical Research, University of Basel

Country where clinical trial is conducted

Lesotho, 

Outcome

Type Measure Description Time frame Safety issue
Other Association of patient-wealth and virologic failure among patients on ART in rural Lesotho Patient wealth will be assessed using the wealth index developed by the Demographic Health Survey Lesotho (http://dhsprogram.com/publications/publication-FR241-DHS-Final-Reports.cfm). Virologic outcome of patients will be stratified by wealth-quintile at enrollment No
Other Virologic outcome of patients on anti-retroviral therapy at decentralized centers as compared to patients followed at the hospitals Patients will be stratified if they were followed at a health center (nurse-led) or at a hospital. at enrollment No
Primary Prevalence of comorbidities among patients on anti-retroviral therapy in rural Lesotho The prevalence of the following comorbidities/conditions will be assessed:
Diabetes Mellitus
Arterial Hypertension
Dyslipidemia
Depression
Alcohol use disorder
Hepatitis B
Hepatitis C
at enrollment No
Primary Prevalence of virologic failure and genotype resistance patterns among patients on anti-retroviral therapy who were not monitored virologically All patients on first-line ART = 6 months will receive viral load testing. Those with a detectable viral load will receive enhanced adherence counselling and again a viral load measurement 3 months after the initial viral load (as recommended by the consolidated WHO-guidelines). In case of persistent virologic failure (2 times detectable viral load) a genotype resitance testing will be done and patients will be switched to second-line ART. This will allow to validate the WHO algorithm for virologic failure in a remote, resource-limited setting. At enrollment No
Secondary 1-year follow-up outcomes of patients with virologic failure and subsequent switch to second-line ART Patients with virologic failure at enrollment will be followed-up after 12-18 months to assess the following outcomes:
clinical outcome: alive and on ART / lost to follow-up / dead
virological outcome: viral load suppressed / viral load detectable
12-18 months after enrollment No
Secondary 1-year outcomes of patients with comorbidities diagnosed at enrollment Patients diagnosed with a specific comorbidity at enrollment (see first primary outcome) will be followed-up to assess their outcome after one year:
clinical outcome: alive and on ART / lost to follow-up / dead
virologic outcome: viral load suppressed / viral load detectable
12-18 months after enrollment No
Secondary Predictors of sustained virologic failure 3 months after a detectable viral load at initial measurement Potential clinical/laboratory predictors to predict sustained virologic failure among patients with a detectable viral load at initial measurement will be collected at enrollment. enrollment + 3 months No
Secondary Association of comorbidities and virologic outcomes among patients on anti-retroviral therapy in rural Lesotho Virologic outcome of anti-retroviral therapy will be compared between patient-groups with and without one or more of the comorbidities listed under the first primary outcome. at enrollment No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A